Published in Blood on April 23, 2009
Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia. Nature (2012) 4.01
Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse. Blood (2011) 2.66
Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia. J Clin Oncol (2010) 2.58
NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant (2010) 1.72
Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation. Blood (2013) 1.70
Phase I study of sorafenib in patients with refractory or relapsed acute leukemias. Haematologica (2010) 1.65
A pharmacodynamic study of sorafenib in patients with relapsed and refractory acute leukemias. Leukemia (2010) 1.61
Activity of ponatinib against clinically-relevant AC220-resistant kinase domain mutants of FLT3-ITD. Blood (2013) 1.52
Unique molecular signatures as a hallmark of patients with metastatic breast cancer: implications for current treatment paradigms. Oncotarget (2014) 1.34
Shortcomings in the clinical evaluation of new drugs: acute myeloid leukemia as paradigm. Blood (2010) 1.33
A phase I trial and pharmacokinetic study of sorafenib in children with refractory solid tumors or leukemias: a Children's Oncology Group Phase I Consortium report. Clin Cancer Res (2012) 1.33
Emergence of polyclonal FLT3 tyrosine kinase domain mutations during sequential therapy with sorafenib and sunitinib in FLT3-ITD-positive acute myeloid leukemia. Clin Cancer Res (2013) 1.23
FLT3 tyrosine kinase inhibitors in acute myeloid leukemia: clinical implications and limitations. Leuk Lymphoma (2013) 1.21
Phase I trial of maintenance sorafenib after allogeneic hematopoietic stem cell transplantation for fms-like tyrosine kinase 3 internal tandem duplication acute myeloid leukemia. Biol Blood Marrow Transplant (2014) 1.20
Outcome of patients with FLT3-mutated acute myeloid leukemia in first relapse. Leuk Res (2009) 1.16
Treatment of FLT3-ITD-positive acute myeloid leukemia relapsing after allogeneic stem cell transplantation with sorafenib. Biol Blood Marrow Transplant (2011) 1.09
FLT3 inhibitors: a story of the old and the new. Curr Opin Hematol (2011) 1.09
FLT3/ITD AML and the law of unintended consequences. Blood (2011) 1.07
A proposal regarding reporting of in vitro testing results. Clin Cancer Res (2013) 1.06
FLT3 inhibition as therapy in acute myeloid leukemia: a record of trials and tribulations. Oncologist (2011) 1.05
Initial testing (stage 1) of the multi-targeted kinase inhibitor sorafenib by the pediatric preclinical testing program. Pediatr Blood Cancer (2010) 1.03
Bench to bedside targeting of FLT3 in acute leukemia. Curr Drug Targets (2010) 1.03
Exploiting cellular pathways to develop new treatment strategies for AML. Cancer Treat Rev (2010) 1.03
Treatment with FLT3 inhibitor in patients with FLT3-mutated acute myeloid leukemia is associated with development of secondary FLT3-tyrosine kinase domain mutations. Cancer (2014) 0.98
Lessons learned from the investigational device exemption review of Children's Oncology Group trial AAML1031. Clin Cancer Res (2012) 0.98
FLT3 inhibitors in the treatment of acute myeloid leukemia: the start of an era? Cancer (2011) 0.97
Treatment of FLT3-ITD acute myeloid leukemia. Am J Blood Res (2011) 0.97
The sorafenib plus nutlin-3 combination promotes synergistic cytotoxicity in acute myeloid leukemic cells irrespectively of FLT3 and p53 status. Haematologica (2012) 0.96
The multikinase inhibitor Sorafenib displays significant antiproliferative effects and induces apoptosis via caspase 3, 7 and PARP in B- and T-lymphoblastic cells. BMC Cancer (2010) 0.91
Salvage therapy using FLT3 inhibitors may improve long-term outcome of relapsed or refractory AML in patients with FLT3-ITD. Br J Haematol (2013) 0.91
Patterns of molecular response to and relapse after combination of sorafenib, idarubicin, and cytarabine in patients with FLT3 mutant acute myeloid leukemia. Clin Lymphoma Myeloma Leuk (2011) 0.89
Molecular diagnosis and risk-adjusted therapy in pediatric hematologic malignancies: a primer for pediatricians. Eur J Pediatr (2011) 0.89
Sorafenib is tolerable and improves clinical outcomes in patients with FLT3-ITD acute myeloid leukemia prior to stem cell transplant and after relapse post-transplant. Am J Hematol (2014) 0.87
Acute myeloid leukaemia: optimal management and recent developments. Drugs (2011) 0.86
Synergistic cytotoxicity of sorafenib with busulfan and nucleoside analogs in human FMS-like tyrosine kinase 3 internal tandem duplications-positive acute myeloid leukemia cells. Biol Blood Marrow Transplant (2014) 0.85
Will FLT3 inhibitors fulfill their promise in acute meyloid leukemia? Curr Opin Hematol (2014) 0.84
The Biology and Targeting of FLT3 in Pediatric Leukemia. Front Oncol (2014) 0.83
Will newer tyrosine kinase inhibitors have an impact in AML? Best Pract Res Clin Haematol (2010) 0.83
Influence of molecular subgroups on outcome of acute myeloid leukemia with normal karyotype in 141 patients undergoing salvage allogeneic stem cell transplantation in primary induction failure or beyond first relapse. Haematologica (2012) 0.82
Toxic effects of sorafenib when given early after allogeneic hematopoietic stem cell transplantation. Blood (2010) 0.82
Targeted therapies in hematology and their impact on patient care: chronic and acute myeloid leukemia. Semin Hematol (2013) 0.82
Cancer stem cells: relevance to clinical transplantation. Curr Opin Oncol (2012) 0.80
Rapid induction of complete molecular remission by sequential therapy with LDAC and sorafenib in FLT3-ITD-positive patients unfit for intensive treatment: two cases and review of the literature. J Hematol Oncol (2013) 0.79
NFATc1 as a therapeutic target in FLT3-ITD-positive AML. Leukemia (2015) 0.79
Emerging FMS-like tyrosine kinase 3 inhibitors for the treatment of acute myelogenous leukemia. Expert Opin Emerg Drugs (2011) 0.79
Mechanisms of apoptosis induction by simultaneous inhibition of PI3K and FLT3-ITD in AML cells in the hypoxic bone marrow microenvironment. Cancer Lett (2012) 0.78
Computer aided drug discovery of highly ligand efficient, low molecular weight imidazopyridine analogs as FLT3 inhibitors. Eur J Med Chem (2015) 0.78
Sorafenib in combination with low-dose-homoharringtonine as a salvage therapy in primary refractory FLT3-ITD-positive AML: a case report and review of literature. Int J Clin Exp Med (2015) 0.76
Haematopoietic cell transplantation with and without sorafenib maintenance for patients with FLT3-ITD acute myeloid leukaemia in first complete remission. Br J Haematol (2016) 0.76
Sorafenib induces paradoxical phosphorylation of the extracellular signal-regulated kinase pathway in acute myeloid leukemia cells lacking FLT3-ITD mutation. Leuk Lymphoma (2015) 0.75
The Challenge of t (6;9) and FLT3-Positive Acute Myelogenous Leukemia in a Young Adult. J Leuk (Los Angel) (2015) 0.75
Molecular and Cellular Mechanisms of Myelodysplastic Syndrome: Implications on Targeted Therapy. Int J Mol Sci (2016) 0.75
Acute myeloid leukemia: advancing clinical trials and promising therapeutics. Expert Rev Hematol (2016) 0.75
Pim kinase inhibition sensitizes FLT3-ITD acute myeloid leukemia cells to topoisomerase 2 inhibitors through increased DNA damage and oxidative stress. Oncotarget (2016) 0.75
Recent advances and novel agents for FLT3 mutated acute myeloid leukemia. Stem Cell Investig (2014) 0.75
New approaches to manipulate minimal residual disease after allogeneic stem cell transplantation. Int J Hematol Oncol (2013) 0.75
FLT3 inhibitors: clinical potential in acute myeloid leukemia. Onco Targets Ther (2017) 0.75
Strategies to reduce relapse after allogeneic hematopoietic cell transplantation in acute myeloid leukemia. Curr Hematol Malig Rep (2013) 0.75
Discovery of a Highly Potent and Selective Indenoindolone Type 1 Pan-FLT3 Inhibitor. ACS Med Chem Lett (2016) 0.75
Sorafenib Induced Hand Foot Skin Rash in FLT3 ITD Mutated Acute Myeloid Leukemia-A Case Report and Review of Literature. Mediterr J Hematol Infect Dis (2014) 0.75
Emerging importance of mutational analysis in myelodysplastic syndrome and acute myelogenous leukemia. Biol Blood Marrow Transplant (2013) 0.75
Translational hematology. Wien Med Wochenschr (2014) 0.75
A phase 2 study incorporating sorafenib into the chemotherapy for older adults with FLT3-mutated acute myeloid leukemia: CALGB 11001. Blood Adv (2017) 0.75
Outcome of FLT3-ITD-positive acute myeloid leukemia: impact of allogeneic stem cell transplantation and tyrosine kinase inhibitor treatment. J Cancer Res Clin Oncol (2016) 0.75
A second generation human haplotype map of over 3.1 million SNPs. Nature (2007) 85.39
A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat Immunol (2005) 27.17
Genome-wide detection and characterization of positive selection in human populations. Nature (2007) 17.27
The beta-catenin/TCF-4 complex imposes a crypt progenitor phenotype on colorectal cancer cells. Cell (2002) 13.92
Genomewide association study of leprosy. N Engl J Med (2009) 8.17
Transcriptional regulation and transformation by Myc proteins. Nat Rev Mol Cell Biol (2005) 7.54
Mapping human genetic diversity in Asia. Science (2009) 7.40
In vivo genome editing using a high-efficiency TALEN system. Nature (2012) 7.11
Updated National Birth Prevalence estimates for selected birth defects in the United States, 2004-2006. Birth Defects Res A Clin Mol Teratol (2010) 7.00
Management of lung nodules detected by volume CT scanning. N Engl J Med (2009) 6.79
KCNQ1 gain-of-function mutation in familial atrial fibrillation. Science (2003) 6.60
Genome-wide association study in a Chinese Han population identifies nine new susceptibility loci for systemic lupus erythematosus. Nat Genet (2009) 6.42
A genome-wide association study of lung cancer identifies a region of chromosome 5p15 associated with risk for adenocarcinoma. Am J Hum Genet (2009) 5.62
Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-study IV. J Clin Oncol (2013) 4.50
Heterogeneity of natural Foxp3+ T cells: a committed regulatory T-cell lineage and an uncommitted minor population retaining plasticity. Proc Natl Acad Sci U S A (2009) 4.25
Cre/loxP-mediated inactivation of the murine Pten tumor suppressor gene. Genesis (2002) 4.23
Stabilization of N-Myc is a critical function of Aurora A in human neuroblastoma. Cancer Cell (2009) 3.92
The SOL Genomics Network: a comparative resource for Solanaceae biology and beyond. Plant Physiol (2005) 3.65
The ubiquitin-specific protease USP28 is required for MYC stability. Nat Cell Biol (2007) 3.63
Statins induce angiogenesis, neurogenesis, and synaptogenesis after stroke. Ann Neurol (2003) 3.54
Treatment of stroke with erythropoietin enhances neurogenesis and angiogenesis and improves neurological function in rats. Stroke (2004) 3.53
Genome characteristics of facultatively symbiotic Frankia sp. strains reflect host range and host plant biogeography. Genome Res (2006) 3.53
Draft genome sequence of chickpea (Cicer arietinum) provides a resource for trait improvement. Nat Biotechnol (2013) 3.41
Liver-specific deletion of negative regulator Pten results in fatty liver and insulin hypersensitivity [corrected]. Proc Natl Acad Sci U S A (2004) 3.40
A low dose of dietary resveratrol partially mimics caloric restriction and retards aging parameters in mice. PLoS One (2008) 3.25
Pten constrains centroacinar cell expansion and malignant transformation in the pancreas. Cancer Cell (2005) 3.15
Negative regulation of the mammalian UV response by Myc through association with Miz-1. Mol Cell (2002) 2.99
The ubiquitin ligase HectH9 regulates transcriptional activation by Myc and is essential for tumor cell proliferation. Cell (2005) 2.85
Significant linkage to compulsive hoarding on chromosome 14 in families with obsessive-compulsive disorder: results from the OCD Collaborative Genetics Study. Am J Psychiatry (2007) 2.84
MYCN regulates oncogenic MicroRNAs in neuroblastoma. Int J Cancer (2008) 2.76
Activation of the hypoxia-inducible factor-1alpha pathway accelerates bone regeneration. Proc Natl Acad Sci U S A (2008) 2.65
Myc represses differentiation-induced p21CIP1 expression via Miz-1-dependent interaction with the p21 core promoter. Oncogene (2003) 2.59
Interaction of KAI1 on tumor cells with DARC on vascular endothelium leads to metastasis suppression. Nat Med (2006) 2.57
Experimental evidence for epitaxial silicene on diboride thin films. Phys Rev Lett (2012) 2.56
Effects of an anti-TSLP antibody on allergen-induced asthmatic responses. N Engl J Med (2014) 2.53
Macrophage autophagy plays a protective role in advanced atherosclerosis. Cell Metab (2012) 2.48
Changes in biophysical and biochemical properties of single bronchial smooth muscle cells from asthmatic subjects. Am J Physiol Lung Cell Mol Physiol (2002) 2.46
Exploration of gene-gene interaction effects using entropy-based methods. Eur J Hum Genet (2007) 2.42
Activated neural stem cells contribute to stroke-induced neurogenesis and neuroblast migration toward the infarct boundary in adult rats. J Cereb Blood Flow Metab (2004) 2.41
Retracted Alveolar macrophages from overweight/obese subjects with asthma demonstrate a proinflammatory phenotype. Am J Respir Crit Care Med (2012) 2.39
A critical role of IFNgamma in priming MSC-mediated suppression of T cell proliferation through up-regulation of B7-H1. Cell Res (2008) 2.38
MicroRNA-101 inhibited postinfarct cardiac fibrosis and improved left ventricular compliance via the FBJ osteosarcoma oncogene/transforming growth factor-β1 pathway. Circulation (2012) 2.36
P25-graphene composite as a high performance photocatalyst. ACS Nano (2010) 2.34
Murine B7-H3 is a negative regulator of T cells. J Immunol (2004) 2.33
Vitellogenin, juvenile hormone, insulin signaling, and queen honey bee longevity. Proc Natl Acad Sci U S A (2007) 2.31
Differential response to neoadjuvant chemotherapy among 7 triple-negative breast cancer molecular subtypes. Clin Cancer Res (2013) 2.30
Enhanced efficiency of generating induced pluripotent stem (iPS) cells from human somatic cells by a combination of six transcription factors. Cell Res (2008) 2.29
Prognostic significance of ASXL1 mutations in patients with myelodysplastic syndromes. J Clin Oncol (2011) 2.26
Self-assembly of CdTe nanocrystals into free-floating sheets. Science (2006) 2.25
Sildenafil (Viagra) induces neurogenesis and promotes functional recovery after stroke in rats. Stroke (2002) 2.24
Transcriptional repression by Myc. Trends Cell Biol (2003) 2.19
Myc-induced proliferation and transformation require Akt-mediated phosphorylation of FoxO proteins. EMBO J (2004) 2.19
The retinoblastoma tumor suppressor modifies the therapeutic response of breast cancer. J Clin Invest (2006) 2.18
The MK5/PRAK kinase and Myc form a negative feedback loop that is disrupted during colorectal tumorigenesis. Mol Cell (2011) 2.17
Genetic variants on 15q25.1, smoking, and lung cancer: an assessment of mediation and interaction. Am J Epidemiol (2012) 2.16
Sonic hedgehog is an autocrine viability factor for myofibroblastic hepatic stellate cells. J Hepatol (2007) 2.16
Loss of the LAT adaptor converts antigen-responsive T cells into pathogenic effectors that function independently of the T cell receptor. Immunity (2009) 2.13
Cyclin D1 splice variants. Differential effects on localization, RB phosphorylation, and cellular transformation. J Biol Chem (2003) 2.12
Systemic lupus erythematosus serum IgG increases CREM binding to the IL-2 promoter and suppresses IL-2 production through CaMKIV. J Clin Invest (2005) 2.08
Elafin is a biomarker of graft-versus-host disease of the skin. Sci Transl Med (2010) 2.08
T(11;18) is a marker for all stage gastric MALT lymphomas that will not respond to H. pylori eradication. Gastroenterology (2002) 2.06
Stromal cell-derived factor 1alpha mediates neural progenitor cell motility after focal cerebral ischemia. J Cereb Blood Flow Metab (2006) 2.06
Matrix metalloproteinase 2 (MMP2) and MMP9 secreted by erythropoietin-activated endothelial cells promote neural progenitor cell migration. J Neurosci (2006) 2.06
PD-L1 expression in triple-negative breast cancer. Cancer Immunol Res (2014) 2.06
Inhibition of IL-17A attenuates atherosclerotic lesion development in apoE-deficient mice. J Immunol (2009) 2.03
Development of a EST dataset and characterization of EST-SSRs in a traditional Chinese medicinal plant, Epimedium sagittatum (Sieb. Et Zucc.) Maxim. BMC Genomics (2010) 2.01
Lactate dehydrogenase B is critical for hyperactive mTOR-mediated tumorigenesis. Cancer Res (2011) 2.00
Impact of visual field loss on health-related quality of life in glaucoma: the Los Angeles Latino Eye Study. Ophthalmology (2007) 2.00
Regulation of innate and adaptive immune responses by MAP kinase phosphatase 5. Nature (2004) 1.99
Features of resolving and nonresolving indeterminate pulmonary nodules at follow-up CT: the NELSON study. Radiology (2013) 1.98
Sustained molecular response with interferon alfa maintenance after induction therapy with imatinib plus interferon alfa in patients with chronic myeloid leukemia. J Clin Oncol (2010) 1.98
CCR2-dependent recruitment of macrophages by tumor-educated mesenchymal stromal cells promotes tumor development and is mimicked by TNFα. Cell Stem Cell (2012) 1.97
Regulatory divergence modifies limb length between mammals. Genes Dev (2008) 1.96
The 21-nucleotide, but not 22-nucleotide, viral secondary small interfering RNAs direct potent antiviral defense by two cooperative argonautes in Arabidopsis thaliana. Plant Cell (2011) 1.95
T-cell tolerance or function is determined by combinatorial costimulatory signals. EMBO J (2006) 1.92
Distribution and speciation of heavy metals in sediments from the mainstream, tributaries, and lakes of the Yangtze River catchment of Wuhan, China. J Hazard Mater (2008) 1.89
Deregulated MYC expression induces dependence upon AMPK-related kinase 5. Nature (2012) 1.88
Chemical characteristics of PM2.5 and PM10 in haze-fog episodes in Beijing. Environ Sci Technol (2006) 1.86
Role of Toll-like receptor 4 in endotoxin-induced acute renal failure. J Immunol (2004) 1.82
Assembly of Weibel-Palade body-like tubules from N-terminal domains of von Willebrand factor. Proc Natl Acad Sci U S A (2008) 1.81
IL-10 triggers changes in macrophage phenotype that promote muscle growth and regeneration. J Immunol (2012) 1.81
Low BCR-ABL expression levels in hematopoietic precursor cells enable persistence of chronic myeloid leukemia under imatinib. Blood (2011) 1.81
The interaction between Myc and Miz1 is required to antagonize TGFbeta-dependent autocrine signaling during lymphoma formation and maintenance. Genes Dev (2010) 1.81
MicroRNA-19a mediates the suppressive effect of laminar flow on cyclin D1 expression in human umbilical vein endothelial cells. Proc Natl Acad Sci U S A (2010) 1.80
Mammalian target of rapamycin regulates murine and human cell differentiation through STAT3/p63/Jagged/Notch cascade. J Clin Invest (2009) 1.80
p38 MAPK/MK2-mediated induction of miR-34c following DNA damage prevents Myc-dependent DNA replication. Proc Natl Acad Sci U S A (2010) 1.77
Prolyl hydroxylase inhibitors increase neoangiogenesis and callus formation following femur fracture in mice. J Orthop Res (2009) 1.76
Copper resistance is essential for virulence of Mycobacterium tuberculosis. Proc Natl Acad Sci U S A (2011) 1.76
Up-regulation of miR-21 mediates resistance to trastuzumab therapy for breast cancer. J Biol Chem (2011) 1.73
Phosphorylated ERM is responsible for increased T cell polarization, adhesion, and migration in patients with systemic lupus erythematosus. J Immunol (2007) 1.73
Long-term follow-up of gastric MALT lymphoma after Helicobacter pylori eradication. J Clin Oncol (2005) 1.72